Artelo Biosciences (ARTL) Expected to Announce Quarterly Earnings on Tuesday

Artelo Biosciences (NASDAQ:ARTL) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 19th. Analysts expect Artelo Biosciences to post earnings of ($0.78) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 20, 2026 at 9:30 AM ET.

Artelo Biosciences Trading Down 4.7%

NASDAQ:ARTL opened at $2.42 on Tuesday. Artelo Biosciences has a 1 year low of $2.40 and a 1 year high of $85.80. The firm’s fifty day simple moving average is $4.98 and its 200 day simple moving average is $5.21. The firm has a market capitalization of $2.27 million, a PE ratio of -0.04 and a beta of 0.05.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Friday, March 27th. Wall Street Zen lowered shares of Artelo Biosciences to a “strong sell” rating in a research note on Saturday, April 25th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $54.00.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.